Antibody response durability following three-dose COVID-19 vaccination in people with HIV receiving suppressive ART
Author:
Lapointe Hope R.ORCID, Mwimanzi FrancisORCID, Cheung Peter K., Sang Yurou, Yaseen Fatima, Speckmaier Sarah, Barad Evan, Moran-Garcia Nadia, Datwani Sneha, Duncan Maggie C., Kalikawe RebeccaORCID, Ennis SiobhanORCID, Young Landon, Ganase Bruce, Omondi F. Harrison, Umviligihozo GiseleORCID, Dong WinnieORCID, Toy Junine, Sereda Paul, Burns Laura, Costiniuk Cecilia T.ORCID, Cooper Curtis, Anis Aslam H., Leung Victor, Holmes DanielORCID, DeMarco Mari L.ORCID, Simons Janet, Hedgcock Malcolm, Prystajecky NatalieORCID, Lowe Christopher F., Romney Marc G.ORCID, Barrios Rolando, Guillemi Silvia, Brumme Chanson J., Montaner Julio S.G.ORCID, Hull Mark, Harris Marianne, Niikura MasahiroORCID, Brockman Mark A.ORCID, Brumme Zabrina L.ORCID
Abstract
ABSTRACTBackgroundLimited data exist regarding longer-term antibody responses following three-dose COVID-19 vaccination, and the impact of a first SARS-CoV-2 infection during this time, in people living with HIV (PLWH) receiving suppressive antiretroviral therapy (ART). We quantified wild-type-(WT), Omicron BA.1- and Omicron BA.5-specific responses up to six months post-third dose in 64 PLWH and 117 controls who remained COVID-19-naive or experienced their first SARS-CoV-2 infection during this time.DesignLongitudinal observational cohort.MethodsWe quantified WT- and Omicron-specific Anti-Spike receptor-binding domain IgG concentrations, ACE2 displacement activities and live virus neutralization at one, three and six months post-third vaccine dose.ResultsThird doses boosted all antibody measures above two-dose levels, but BA.1-specific responses remained significantly lower than WT-specific ones, with BA.5-specific responses lower still. Serum IgG concentrations declined at similar rates in COVID-19-naive PLWH and controls post-third dose (median WT- and BA.1-specific half-lives were between 66-74 days for both groups). Antibody function also declined significantly yet comparably between groups: six months post-third dose, BA.1-specific neutralization was undetectable in >80% of COVID-19 naive PLWH and >90% of controls. Breakthrough SARS-CoV-2 infection boosted antibody concentrations and function significantly above vaccine-induced levels in both PLWH and controls, though BA.5-specific neutralization remained significantly poorer than BA.1 even post-breakthrough.ConclusionsFollowing three-dose COVID-19 vaccination, antibody response durability in PLWH receiving ART is comparable to controls. PLWH also mounted strong responses to breakthrough infection. Due to temporal response declines however, COVID-19-naive individuals, regardless of HIV status, would benefit from a fourth dose within 6 months of their third.
Publisher
Cold Spring Harbor Laboratory
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|